We conducted a phase II study of docetaxel in combination with everolimus, a mammalian
target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung …

Background Bevacizumab and erlotinib have been demonstrated to prolong overall survival
in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four …

Background and Objectives: It is generally accepted that inflammatory cells found in the
tumor microenvironment are involved in the neoplastic process, promoting cell proliferation …

Celecoxib exhibits cancer preventive and therapeutic effects in animal models and clinical
trials. It presumably acts through selective inhibition of cyclooxygenase-2 (COX-2) and …

Combinatorial therapies that target multiple signaling pathways may provide improved
therapeutic responses over monotherapies. Celecoxib and curcumol are two highly …

Introduction: The phosphotidylinositol-3 kinase/serine-threonine kinase (AKT)/mammalian
target of rapamycin signaling pathway is frequently altered in non–small-cell lung cancer …

Purpose The role of second-line chemotherapy in patients with non-small cell lung cancer
(NSCLC) and preexisting interstitial pneumonia (IP) previously treated with platinum-based …

Systemic chemotherapy with platinum-based combinations provides modest improvements
in both survival and quality of life for patients with advanced non-small cell lung cancer …

Background Treatment of patients who have locally advanced non–small-cell lung cancer
and compromised performance status or weight loss (WL) is challenging. This study was …